Ziyuglycoside II is a triterpenoid saponin compound extracted from Sanguisorba officinalis L.. Ziyuglycoside II induces reactive oxygen species (ROS) production and apoptosis. Anti-inflammation and anti-cancer effect[1].
Ziyuglycoside II (10-60 μM; 24 h and 48 h) inhibits MDA-MB-435 cells growth in a dose-dependent manner. The IC50 of Ziyuglycoside II at 24 h and 48 h is 5.92 μM and 4.74 μM, respectively[1]. Ziyuglycoside II (5-25 μM) induces G0/G1 and S phase arrest in MDA-MB-435 cells at 24 h[1]. Ziyuglycoside II (5-25 μM; 24 hours) significantly increases apoptotic rate of MDA-MB-435 cells[1].Ziyuglycoside II (5-25 μM; 24 hours) increases expressions of both p53 and p21 in MDA-MB-435 cells, which effect is dose-dependent[1].
References:
[1]. Zhu X, et al. Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int J Mol Sci. 2013 Sep 3;14(9):18041-55.
[2]. Zhu X, et al. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells. Toxicol Lett. 2014 May 16;227(1):65-73.